Search

Choose your membership

Wherever you are in the world, you can join our vibrant community and benefit from our rigorous resources and career-enhancing opportunities.

Read more

BENIGN HEMATOLOGY in 2023 and beyond

The term "benign hematology" has traditionally been used to refer to non-malignant blood disorders. However, over the past few years, questions have been raised as to the appropriate nomenclature for this category of diseases.

Read more

EHA2024 Scientific Congress Report

The European Hematology Association (EHA) is delighted to present the EHA2024 Scientific Congress Report titled “EHA Perspectives on Emerging Technologies in Hematology.

Read more

Policy & advocacy

Our mandateEHA’s policy and advocacy work is guided by the European Affairs Committee, which sets the priorities, formulates positions and actively contributes to engagement with policy makers and stakeholders.

Read more

From bedside to Brussels: hematology at the forefront of EU health policy

Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.

Read more

Advances from genome sequencing are paving the way to personalized treatment for leukemia and pre-leukemia

In acute myeloid leukemia (AML) our understanding of how modifications to DNA molecules that do not result in sequence change (i. e.

Read more